Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 98

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 3
Chunk 98
---
 respect to the initial post-closing trades. Therefore, buy
and sell orders submitted prior to and at the opening of initial post-closing trading of our securities did not have the benefit of being
informed by a published price range or a price at which the underwriters initially sold shares to the public, as would be the case in
an underwritten initial public offering. There were no underwriters assuming risk in connection with an initial resale of our securities
or helping to stabilize, maintain or affect the public price of our securities following the closing. No assurance can be given that brokerage
firms will, in the future, want to conduct any offerings on our behalf.

Such differences from an underwritten
public offering may present material risks to unaffiliated investors that would not have existed if we became a publicly listed company
through an underwritten initial public offering instead of completion of a Business Combination. Further, all of these differences from
an underwritten public offering of our securities have resulted in diminished investor demand, inefficiencies in pricing and a more volatile
public price for our securities.

We may issue additional ordinary shares
or other equity securities without seeking approval of our shareholders, which would dilute your ownership interests and may depress the
market price of the ordinary shares.

As of March 1, 2025, we had
warrants outstanding to purchase up to an aggregate of 15,747,561 ordinary shares, as well as outstanding ESOP grants to our employees,
directors and service providers, of options to purchase a total of 14,702,335 ordinary shares and 878,302 RSUs. Further, we may choose
to seek third-party financing to provide additional working capital for our business, in which event we may issue additional equity securities.
We may also issue additional ordinary shares or other equity securities of equal or senior rank in the future for any reason.

If we or any of our subsidiaries are characterized
as a Passive Foreign Investment Company (“ PFIC”) for U. S. federal income tax purposes, U. S. Holders may suffer adverse tax
consequences.

A non-U. S. corporation generally
will be treated as a PFIC for U. S. federal income tax purposes, in any taxable year if either (1) at least 75% of its gross income for
such year is passive income or (2) at least 50% of the value of its assets (generally based on an average of the quarterly values of the
assets) during such year is